Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 17/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 16/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 10/20 | 0.54 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.41 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.37 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27875791 | 0.91 | LPAR3 (0.58) | LPAR3LPAR2LPAR1LPAR5LPAR6 | |
| SCHEMBL899753 | 0.88 | — | — | |
| Propyl Phosphate SCHEMBL57642 | 0.88 | — | — | |
| Propyl Phosphate SCHEMBL28303359 | 0.88 | LPAR3 (0.65) | LPAR3LPAR2LPAR1LPAR5 | |
| Propyl Phosphate SCHEMBL10354165 | 0.85 | — | — | |
| Propyl Phosphate SCHEMBL11529608 | 0.85 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LPAR5 | |
| Propyl Phosphate SCHEMBL11801614 | 0.85 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LPAR5 | |
| Propyl Phosphate SCHEMBL7947920 | 0.85 | — | — | |
| Propyl Phosphate SCHEMBL22556635 | 0.85 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LPAR5 | |
| Propyl Phosphate SCHEMBL11383638 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-2504435-B1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10421962-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190040385-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TARGETING P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | disclosed |
| EP-2895608-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-10144928-B2 | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | BIO-LAB LTD. (IL) | 2018-08-28 | — | — | US | disclosed |
| WO-2013020097-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS | QUARK PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012170957-A2 | RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| US-20120283309-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2509991-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2504435-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | Quark Pharmaceuticals, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012078536-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011163436-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
| WO-2011072082-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011066475-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | LPAR3 3223/4885LPAR2 4209/4885LPAR1 4282/4885 |
| US-10093923-B2 | Modulation of HSP47 expression | HSPA1A, HSPH1, HSPA8 | LPAR3 3223/4885LPAR2 4209/4885LPAR1 4282/4885 |
| US-20120283309-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | SNRPE, TSG101, RNMT | LPAR3 761/4885LPAR2 1190/4885LPAR1 968/4885 |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | RNASEH1, RNGTT, EIF2AK2 | LPAR3 1725/4885LPAR2 1505/4885LPAR1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.